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Abstract: Mitochondria are organelles involved in a variety of cellular functions that are central to the life and death of a 
cell. Oxidative phosphorylation (OXPHOS), the main energy provider of the cell, takes place inside mitochondria and is 
known to be altered in carcinogenesis and tumor progression contributing to the “metabolic reprogramming”, one of the 
hallmarks of cancer cells. Due to the central role of energy metabolism in cancer cell pathogenesis, mutations in the 
mitochondrial genome (mtDNA), which encodes for essential components of the OXPHOS pathway, have been 
suggested to play a role in many cancers, including prostate cancer. Recent studies provide evidence for increased 
levels of mutant mtDNA in prostate cancer patients with higher Gleason grade and relapse, as well as in bone metastatic 
sites. In this review, we will provide an overview of recent studies investigating the presence of mtDNA mutations in 
prostate cancer cells and their significance in the context of clinical pathological features of prostate cancer.  
Keywords: Mitochondria, Mitochondrial DNA mutations, Prostate cancer, Mitochondrial genome, Nuclear genome. 
INTRODUCTION 
Mitochondria are the powerhouse of the cells, being 
the main supply of energy as ATP. Besides energy 
production, mitochondria are main actors in the 
execution of apoptosis and regulate several anabolic 
pathways, including biosynthesis of aminoacids, 
nucleic acids, lipids, and substrates such as NADH and 
NADPH [1, 2]. Mitochondria are semi-autonomous 
organelles containing their own genome, a 16,569 bp 
double-stranded, circular DNA molecule (mtDNA) 
which can replicate independently and that encodes for 
13 proteins essential for the mitochondrial respiratory 
chain [NADH dehydrogenase 1, 2, 3, 4, 4L, 5, 6 (ND1, 
2, 3, 4, 4L, 5, 6); Cytochrome b, Cytochrome oxidase I, 
II, III, ATPase 6, 8], 22 transfer RNAs (tRNAs) and 2 
ribosomal RNAs (12 S and 16S rRNAs) required for 
mitochondrial protein synthesis (Figure 1). In addition, 
the mtDNA has a non-coding control region (D-loop) 
with regulatory regions for mtDNA replication. 
Mitochondria contain a variable number of mtDNA 
molecules, depending on the cell/tissue type, with an 
average of 5 molecules/mitochondrion. Within the 
same cell, some mitochondria may contain mtDNA 
mutations while others have wild-type mtDNA, a 
feature known as “heteroplasmy”. “Homoplasmy” 
instead indicates when a cell or a cell subpopulation 
contains a uniformly normal or mutant mtDNA pool.  
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Although mitochondria contain their own genome, they 
are semi-autonomous because most of the proteins 
residing in mitochondria are encoded by the nuclear 
DNA. So far, a number of genetic and metabolic 
mitochondrial modifications have been described in 
cancer cells, affecting both the mitochondrial and the 
nuclear genome, and they have been implicated in 
metabolic reprogramming as well as in the response of 
cancer cells to chemotherapeutic drugs [3-6].  
 
Figure 1: Human Mitochondrial DNA. The human mtDNA is 
a 16,569 bp circular molecule encoding for 13 proteins of the 
mitochondrial respiratory chain, 2 rRNA (12S and 16S rRNA) 
and 22 tRNAs (white rectangles). The D-loop sequence 
contains regulatory regions. ND, NADH dehydrogenase; 
COX, cytochrome oxidase; ATP, ATPase. 
More than 70 years ago, Otto H. Warburg 
demonstrated that neoplastic cells have an altered 
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energy metabolism: he observed that instead of using 
an oxidative metabolism, cancer cells convert glucose 
into lactate even in the presence of high oxygen 
tension. This “Warburg effect” is referred to as 
“metabolic reprogramming” and is a hallmark of cancer 
[7]. In his pioneering research, Warburg hypothesized 
that mitochondrial dysfunction and consequent cell 
inability to effectively oxidize glucose carbon to CO2 
was crucial for the metabolic shift to glycolysis. More 
recently, the metabolic shift has been shown to occur 
even in the presence of functional mitochondria [8-10]. 
The metabolic reprogramming would indeed provide a 
biosynthetic advantage to tumor cells diverting energy 
substrates into key anabolic reactions required for 
differentiation, proliferation and growth [8-11]. As such, 
carbon and nitrogen derived from glucose and 
glutamine would be used for amino acid, fatty acid and 
nucleic acid synthesis, thus supporting cancer growth 
and development. In turn, the increase in lactate 
production due to the metabolic switch to glucose 
fermentation would promote acidification of the micro- 
environment fostering local invasion and metastasis.  
Prostate cancer is the most commonly diagnosed 
malignancy in men of the Western world and a major 
cause of cancer death. Elevated serum prostate 
specific antigen (PSA) and/or abnormal digital rectal 
examination are currently used as the rationale for 
needle biopsy, histopathological examination and 
Gleason scoring. The latter is a grading system based 
on the histological architectural pattern of the prostate 
glands and it is used for prognosis: low Gleason grade 
indicates a well differentiated tumor that will probably 
have a biological behavior close to normal, thus not 
very aggressive; a high Gleason grade instead predicts 
a more aggressive cancer. Lack of availability of 
prognostic biomarkers as well as the extreme 
heterogeneity of this disease make prostate cancer 
management complicated. Until recently, biomarker 
discovery has been focused on the nuclear genome 
with little attention paid to the mitochondrial genome. 
Recently, studies on somatic mtDNA mutations have 
become an important aspect in cancer research 
because mtDNA mutations might have pathological 
significance and/or might serve as biomarkers for 
tumor detection and progression. While it was evident 
that mtDNA mutations are acquired during prostate 
tumorigenesis and cancer progression [12-14], only 
recently the potential prognostic value of mtDNA 
mutations has been underscored. In this review we will 
provide an update of studies published in the last years 
(2010-2016) underlying the significance of mtDNA 
mutations in the etiopathology and prognosis of 
prostate cancer. 
METHODS 
A comprehensive search was carried out using 
PubMed and Google Scholar databases to identify 
pertinent articles within the timeframe 2010-2016. The 
following terms and their combinations were used: 
“prostate cancer”, “prostate carcinoma” and 
“mitochondrial DNA mutations”. Inclusion criteria were 
studies reporting assessment of the somatic nature of 
tumor mutations in prostate cancer and correlations 
with clinical presentation of prostate cancer (staging, 
PSA levels, relapse).  
The search resulted in a total of 38 potentially 
relevant articles. After examining their content, 32 
articles were excluded according to the inclusion 
criteria, leaving the remaining 6 included in this review. 
RESULTS AND DISCUSSION 
MtDNA Mutations in Prostate Cancer 
Prostate cancer is typically associated with aging. 
Because mtDNA depletion and deletion mutations 
accumulate with age in many tissues of the body, a 
potential link between prostate cancer and mtDNA 
mutations has been suggested [15]. Heteroplasmic 
large deletion mutant mtDNA is indeed very common in 
prostate cancer [16]. Acquired mtDNA mutations have 
been reported to accumulate in prostate carcinoma [13, 
14] at a rate approximately 55-fold higher than nuclear 
DNA [17] and are more frequent in prostate cancer, 
after gastric and hepatic carcinomas, than any other 
human cancer [12].  
To understand the role of somatic mtDNA mutations 
in prostate cancer, Kloss-Brandstatter A. et al. [18] 
have analyzed frequency and nature of somatic mtDNA 
mutations and their suitability for monitoring malignant 
transformation, tumor progression, and metastasis in 
30 prostate cancer patients (Table 1). The authors 
sequenced the entire mitochondrial genome in macro-
dissected prostate cancer tissue with varying Gleason 
scores as well as distant benign prostate cells by using 
a high-quality sequencing strategy, able to detect low 
levels of heteroplasmy. Out of 30 patients, 22 showed 
mtDNA point or length heteroplasmies on 39 nucleotide 
positions for a total of 41 somatic mutations. To 
exclude a germline origin of the mutations, blood 
samples from 10 patients with somatic tumor mutations 
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were collected and mtDNA from white blood cells was 
sequenced: they all showed a mtDNA profile identical 
to benign prostate cells and were free of somatic 
mtDNA tumor mutations. The control region (D-loop) 
showed a low degree of somatic mutations, with only 
three point mutations detected. Seven mutations were 
instead detected within the two rRNA genes. 
Intriguingly, none of the mutations identified in 16S 
rRNA were previously observed in the human 
phylogeny overseeing data from 5140 individuals, 
suggesting a potentially pathological role of these 
mutations in prostate cancer. In particular, the somatic 
deletion at position m.2150_2151delTA is located in the 
GTPase-associated center, which is involved in binding 
EFG, the elongation factor that catalyzes the 
translocation oftRNAs on the ribosome. This mutation 
might thus impair mitochondrial protein synthesis. Five 
somatic mutations were mapped within tRNA genes; 
among these, m. T10436Y was located within the 
anticodon of mitochondrial (MT)-TR and changed the 
arginine anticodon to a glutamine anticodon, likely 
resulting in a misincorporation of arginine at glutamine 
codons; m.G1623R was located in the D-stem of MT-
TV and could disrupt a Watson-Crick base pair with a 
possible impact on the tRNA D-loop, thus affecting the 
conformation of the tRNA. Finally, in the context of 
protein-coding mtDNA regions, the mutation m. 
G8184R in MT-Cytochrome oxidase II was found in the 
benign tissue as well as in the tumor tissue from the 
prostate gland and the seminal vesicle from a patient: 
the amount of the mutated nucleotide increased from 
benign tissue (15%) to prostate tumor (30%) to seminal 
vesicle tumor (40%). A similar trend was found for the 
MT-ATP synthase 6 mutation m.C870Y: the benign 
tissue exhibited 40% of the mutated nucleotide, but in 
the cancerous tissue the mutated mtDNA was 
predominant, supporting the hypothesis that the 
proportion of mutated mtDNA increases with 
malignancy [18]. 
Arbini A. et al. [19] screened 12 benign prostate 
hyperplasias and 24 prostate carcinoma specimens for 
the presence of large mtDNA deletions. Large mtDNA 
deletions, absent or present in low number (<2) in 
benign prostates, were significantly increased in 
prostate cancer tissues but not in the corresponding 
mtDNA from peripheral blood lymphocytes, confirming 
their somatic origin and further supporting the 
hypothesis that prostate cancer cells with a high mutant 
mtDNA load may be positively selected during 
tumorigenesis. 
Arnold R.S. et al. [20] sequenced the mtDNA from 
autopsy specimens of 10 prostate cancer patients with 
late stage disease and bone metastases. For 9 out of 
10 patients, mtDNA from four different tissues was 
sequenced: primary prostate cancer, a soft tissue 
metastasis, a bone metastasis and a normal tissue as 
a healthy control. In the 10th patient, primary prostate 
was not available, but both soft and bone metastatic 
sites were sequenced as well as skin as the uninvolved 
tissue. Some mutations were identified in the primary 
tumor and in the two metastatic sites but at different 
heteroplasmic levels. For example, in one patient the 
G9820A somatic mutation was heteroplasmic in the 
primary prostate tissue and lymphnode metastasis but 
reached homoplasmy in the bone metastatic site. 
Overall, significantly increased number of mtDNA 
somatic mutations was detected in the bone metastatic 
sites compared to the primary tumor. Intriguingly, one 
mtDNA nucleotide position was mutated in 77% of 
bone samples: A10398G (Thr in Ala) in the ND3 gene 
of the respiratory Complex I. The effect of this single 
mutation on cancer growth was previously tested in a 
breast cancer model: a cybrid cell line with the 
A10398G mutation displayed cell cycle delay, 
increased ROS levels, decreased mitochondrial 
membrane potential, increased resistance to apoptosis 
and increased metastatic potential in mice [21]. The 
results reported by Arnold et al. [20] suggest that this 
mutation may enable prostate cancer to metastasize to 
the bone, indicating a selective pressure exerted by the 
bone microenvironment for metastatic cells that had 
acquired the G10398A mtDNA mutation.  
McCrow J.P. et al. [22] performed deep sequencing 
analysis of mtDNA in prostate tissue specimens and 
matched blood samples from 87 South African men, 
and identified 144 somatic mtDNA single nucleotide 
variants, of which 80 were present in 39 men with 
aggressive prostate cancer. The mutations identified 
occurred along the entire mtDNA. In an independent 
study, Kalsbeek A.M.F. et al. [23] have recently 
confirmed that total acquired genomic burden, rather 
than specific mtDNA mutations, is increased in prostate 
cancer progression and has diagnostic significance. 
They used next-generation sequencing to analyze the 
mtDNA from prostate tissue and matched blood 
samples of 115 men who underwent radical 
prostatectomy. In the study, 74 prostate somatic 
mtDNA variants were identified in 50 patients, 
distributed across the entire genome.  
It should be pointed out that a recent study does not 
support a role for genetic variations of the 
Mitochondrial Genome Mutations and Pathological Features of Prostate Cancer World Journal of Oncology Research, 2016, Vol. 3    43 
mitochondrial genome in the risk of prostate cancer 
[24]. In this study, the potential role of the mitochondrial 
genome and the risk of prostate cancer were examined 
in 4.086 prostate cancer cases and 3.698 controls from 
the Multiethnic Cohort, by testing 350 Single Nucleotide 
Polymorphisms (SNPs) in 5 different ethnic 
populations: Europeans, Africans, Native Hawaiians, 
Latinos and Asian Americans. The mtDNA-associated 
OXPHOS pathway and genes were not associated with 
prostate cancer risk.  
Taken together, these studies imply that, while the 
presence of germline mtDNA variants does not 
increase the risk of prostate cancer per se’, newly 
acquired somatic mtDNA variants may promote 
prostate cancer progression to an aggressive disease.  
MtDNA Mutations and PSA Levels, Gleason Grade 
and Relapse 
Acquired mtDNA mutations are associated with 
biochemical indicators of aggressive prostate 
carcinoma and may enhance prostate cancer bone 
metastasis [20]. 
Kloss-Brandstatter A. et al. [18] observed a 
tendency to higher Gleason scores in tumors with a 
somatic mutation in a mtDNA-encoded rRNA. In 
addition, patients with a somatic tRNA mutation had a 
significantly higher PSA value at diagnosis than 
patients without it (average 14.25 ng/ml versus 7.15 
ng/ml; p = 0.004). Mutations in mtDNA-encoded tRNAs 
and rRNAs may negatively affect the mitochondrial 
function because they are essential for mitochondrial 
protein synthesis, thus resulting in a reduction or 
inhibition of oxidative phosphorylation.  
McCrow J.P. et al. [22] found that both the number 
and frequency of somatic mtDNA single nucleotide 
variations were associated with higher pathological 
stage and extremely elevated serum PSA levels in men 
with African ancestry. The authors provide evidence 
that prostate cancer progression is likely characterized 
by accumulation of mtDNA mutations in the entire 
Table 1: Characteristics of the Included Studies 
Study # Samples Study Design Results 
Kloss-Brandstatter 
A. et al. [18] 30 
Sequencing of mtDNA in prostate cancer tissue 
and distant benign prostate cells and matched 
blood cells by using a high-quality sequencing 
strategy, able to detect low levels of heteroplasmy.  
22 specimens had mtDNA point or length 
heteroplasmies on 39 nucleotide positions for a 
total of 41 somatic mutations. Tumors with 
somatic mutation in mtDNA-encoded rRNA or 
tRNA had higher Gleason grade. 
Arbini A.  
et al. [19]  36 
Long-PCR analysis of mtDNA from 12 benign 
prostatic hyperplasias and 24 prostate cancer 
specimens and matched blood samples for 
detection of somatic large mtDNA deletions.  
Somatic large mtDNA deletions were 
significantly increased in prostate cancer 
tissues. 
Arnold R.S.  
et al. [20]  10 
Sequencing of mtDNA from four different tissues 
(primary prostate cancer, a soft tissue metastasis, 
a bone metastasis and a normal tissue as a 
healthy control) derived from autopsy specimens of 
prostate cancer patients with late stage disease 
and bone metastases. 
Increased number of mtDNA somatic mutations 
was detected in the bone metastatic sites 
compared to the primary tumor. Mutation 
A10398G in the ND3 gene of the respiratory 
Complex I was mutated in 77% of bone 
metastatic samples. 
McCrow J.P.  
et al. [22]  87 
Sequencing of mtDNA in prostate tissue 
specimens and matched blood samples from 87 
South African men. 
144 somatic mtDNA single nucleotide variants 
were identified: 80 of them occurred in 39 men 
with aggressive prostate cancer. Number and 
frequency of somatic mtDNA mutations were 
associated with higher pathological stage and 
elevated PSA levels. 
Kalsbeek A.M.F. 
 et al. [23]  115 
Next-generation sequencing of mtDNA from 
prostate tissue and matched blood samples of 115 
men who underwent radical prostatectomy.  
74 prostate somatic mtDNA variants were 
identified in 50 patients, distributed across the 
entire genome. Significant correlation was found 
between the total amount of acquired mtDNA 
variants and elevated Gleason score at 
diagnosis and biochemical relapse. 
Giorgi E.E.  
et al. [24] 7.784 
350 Single Nucleotide Polymorphisms (SNPs) 
were tested in 4.086 prostate cancer cases and 
3.698 controls in 5 ethnic populations: Europeans, 
Africans, Native Hawaiians, Latinos and Asian 
Americans.  
SNPs in mtDNA-associated OXPHOS genes 
were not associated with increased prostate 
cancer risk. 
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genome rather than in “hot-spots”. Consistently with 
this hypothesis, Kalsbeek A.M.F. et al. [23] have 
reported that the number and cumulative frequency of 
single nucleotide variants in the mtDNA may 
independently predict prostate cancer presentation, 
with significant diagnostic potential for aggressive 
cancer. In particular, a significant positive correlation 
was found between the total amount of acquired 
mtDNA variants and elevated Gleason score at 
diagnosis and biochemical relapse. The total somatic 
mtDNA variant burden provided a diagnostic and 
prognostic correlation, improving relapse prediction in 
combination with Gleason score.  
Further studies aimed at determining and cataloging 
the spectrum and combination of prostate cancer-
associated mtDNA variants as well as their pathological 
significance in populations of different ethnicity and 
genetic backgrounds may provide significant clinical 
potential in terms of improving diagnosis and 
prognosis. 
CONCLUSIONS 
Prostate cancer is diagnosed in about 80% of men 
at age 80 (www.webmd.com/prostate-cancer) and it 
represents the fifth leading cause of cancer-related 
deaths in men worldwide. Novel therapeutic strategies 
have improved the survival of men with prostate 
cancer; however, a subset of prostate cancer patients 
experience disease relapse and development of 
metastases invariably resistant to current therapies. 
Consequently, understanding the molecular 
mechanisms and genetic alterations that promote 
prostate cancer cell progression towards this lethal 
stage of disease is essential to develop new 
therapeutics that will improve the clinical outcome of 
this disease. As described in this review, recent studies 
provide evidence for increased levels of mutant mtDNA 
in prostate cancer patients with higher Gleason grade 
and relapse, as well as in diagnosed bone metastatic 
sites. Further studies aimed at assessing the spectrum 
of prostate cancer-associated mtDNA variants and their 
pathological significance in the progression of prostate 
cancer to lethal metastatic disease may provide new 
tools to achieve more accurate diagnosis and 
prognosis.  
It is also worth mentioning recent studies that, 
though in early preclinical experimentation, have raised 
the possibility of editing the mitochondrial genome by 
using mitochondria-targeted nucleases (TALENs and 
ZFNs) [25-28]. These approaches have been able to 
reduce the load of mutant mtDNA in affected tissues, 
with important clinical implications for the future 
treatment of patients affected by “mitochondrial” 
diseases, including metastatic prostate cancer. 
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